Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice

References

• Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet361(9369), 1629–1641 (2003).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet365(9455), 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet362(9395), 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C et al. Effects of different blood pressure- lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165(12), 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet373(9667), 929–940 (2009).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension41(6), 1178–1179 (2003).
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br. Med. J.328(7440), 634–640 (2004).
   PubMed Web of Science ®Google Scholar
• Palmer BF. Improving BP control with combined renin–angiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease. Am. J. Cardiovasc. Drugs8(1), 9–14 (2008).
   PubMed Web of Science ®Google Scholar
• Struijker-Boudier HA, Ambrosioni E, Holzgreve H et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity–mortality trials? Int. J. Clin. Pract.61(9), 1592–1602 (2007).
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA289(18), 2363–2369 (2003).
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol.52(22), 1749–1757 (2008).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension51(6), 1403–1419 (2008).
   PubMed Web of Science ®Google Scholar
• Whyte JL, Lapuerta P, L’Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988–1994. J. Clin. Hypertens. (Greenwich) 3(4), 211–216 (2001).
   PubMedGoogle Scholar
• Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension43(1), 10–17 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper RS, Wolf-Maier K, Luke A et al. An international comparative study of blood pressure in populations of European vs. African descent. BMC Med.3, 2 (2005).
   PubMed Web of Science ®Google Scholar
• Boersma E, Keil U, De Bacquer D et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J. Hypertens.21(10), 1831–1840 (2003).
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J. Hypertens.25(7), 1491–1498 (2007).
   PubMed Web of Science ®Google Scholar
• Gorostidi M, Sobrino J, Segura J et al. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J. Hypertens.25(5), 977–984 (2007).
   PubMed Web of Science ®Google Scholar
• ALLHATOfficers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Tocci G, Giovannelli F, Sciarretta S et al. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int. J. Clin. Pract.63(2), 207–216 (2009).
   PubMed Web of Science ®Google Scholar
• Volpe M, Notaro LA, Tocci G et al. The Reassessment of Antihypertensive Chronic Therapy (REACT) Study: an Italian observational study on hypertension management in patients with established therapy. High Blood Pressure & Cardiovascular Prevention11(4), 175–185 (2004).
   Google Scholar
• Mancia G, Parati G, Pomidossi G et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension9(2), 209–215 (1987).
   PubMed Web of Science ®Google Scholar
• Borghi C, Dormi A, D’Addato S, Gaddi A, Ambrosioni E. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J. Hypertens.22(9), 1707–1716 (2004).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Staessen JA, White WB, Imai Y, O’Brien ET. Properly defining white coat hypertension. Eur. Heart J.23(2), 106–109 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, Bombelli M, Facchetti R et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension54(2), 226–232 (2009).
   PubMed Web of Science ®Google Scholar
• Veglio F, Rabbia F, Riva P et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin. Exp. Hypertens.23(3), 203–211 (2001).
   PubMed Web of Science ®Google Scholar
• Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am. J. Hypertens.14(12), 1263–1269 (2001).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit. Rev. Clin. Lab. Sci.44(1), 1–85 (2007).
   PubMed Web of Science ®Google Scholar
• Locatelli F, Manzoni C, Marcelli D. Treatment of hypertension in chronic renal insufficiency. J. Nephrol.10(4), 220–223 (1997).
   PubMed Web of Science ®Google Scholar
• Fournier A, el Esper N, Makdassi R et al. Hypertension and progression of renal insufficiency. Nephrol. Dial. Transplant.9(Suppl. 3), 28–34 (1994).
   PubMed Web of Science ®Google Scholar
• London GM, Guerin AP, Pannier B, Marchais SJ, Safar ME. Large artery structure and function in hypertension and end-stage renal disease. J. Hypertens.16(12 Pt 2), 1931–1938 (1998).
   PubMed Web of Science ®Google Scholar
• Brown MA, Whitworth JA. Hypertension in human renal disease. J. Hypertens.10(8), 701–712 (1992).
   PubMed Web of Science ®Google Scholar
• Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr. Hypertens. Rep.10(6), 496–503 (2008).
   PubMed Web of Science ®Google Scholar
• Chun TY, Pratt JH. Hyperaldosteronism: a commonly occurring underlying feature of essential hypertension and the metabolic syndrome? Curr. Opin. Endocrinol. Diabetes Obes.14(3), 210–212 (2007).
   PubMedGoogle Scholar
• Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N. Engl. J. Med.355(4), 385–392 (2006).
   PubMed Web of Science ®Google Scholar
• Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet371(9628), 1921–1926 (2008).
   PubMed Web of Science ®Google Scholar
• Kittisupamongkol W. Secondary causes of resistant hypertension. Arch. Intern. Med.169(7), 717 (2009).
   PubMedGoogle Scholar
• Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog. Cardiovasc. Dis.51(5), 371–380 (2009).
   PubMed Web of Science ®Google Scholar
• Baguet JP, Levy P, Barone-Rochette G et al. Masked hypertension in obstructive sleep apnea syndrome. J. Hypertens.26(5), 885–892 (2008).
   PubMed Web of Science ®Google Scholar
• de Leeuw PW, Gaillard CA, Birkenhager WH. Drug-induced hypertension. Neth. J. Med.43(Suppl. 1), S39–S43 (1993).
   PubMed Web of Science ®Google Scholar
• Berecek KH, Farag A, Bahtiyar G, Rothman J, McFarlane SI. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr. Hypertens. Rep.6(3), 211–212 (2004).
   PubMed Web of Science ®Google Scholar
• Lane DA, Beevers DG. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J. Hypertens.25(12), 2515–2516 (2007).
   PubMed Web of Science ®Google Scholar
• George J, Struthers AD. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin. Pharmacother.8(17), 3053–3059 (2007).
   PubMed Web of Science ®Google Scholar
• Antonio Costa J, Rodilla E, Perez-Lahiguera F, Maria Pascual J. Eplerenone in resistant hypertension with previous spironolactone intolerance. Med. Clin. (Barc.) 132(19), 756–757 (2009).
   PubMed Web of Science ®Google Scholar
• Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation116(3), 268–275 (2007).
   PubMed Web of Science ®Google Scholar
• Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension49(4), 839–845 (2007).
   PubMed Web of Science ®Google Scholar
• Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens.16(11 Pt 1), 925–930 (2003).
   PubMed Web of Science ®Google Scholar
• Gaddam K, Pimenta E, Thomas SJ et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. DOI: 10.1038/jhh.2009.96 (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig.29(6), 381–391 (2009).
   PubMed Web of Science ®Google Scholar
• Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig.29(1), 11–25 (2009).
   PubMed Web of Science ®Google Scholar
• Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv. Ther.25(5), 399–411 (2008).
   PubMed Web of Science ®Google Scholar
• Calo LA, Bertipaglia L, Pagnin E et al. Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients. Clin. Exp. Hypertens.28(2), 181–188 (2006).
   PubMed Web of Science ®Google Scholar
• Pessina AC, Ciccariello L, Perrone F et al. Clinical efficacy and tolerability of α-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr. Metab. Cardiovasc. Dis.16(2), 137–147 (2006).
   PubMed Web of Science ®Google Scholar
• Campo C, Segura J, Roldan C et al. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. Blood Press. Suppl.2, 16–21 (2003).
   PubMedGoogle Scholar
• Oparil S, Barr E, Elkins M et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin. Ther.18(4), 608–625 (1996).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Tocci G, Palano F, Pagannone E et al. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev. Cardiovasc. Ther.7(2), 115–123 (2009).
   PubMedGoogle Scholar
• Volpe M. Cardiovascular risk in hypertension – can we ask for more?: Focus on aliskiren. High Blood Pressure & Cardiovascular Prevention15(4), 255–268 (2008).
   PubMedGoogle Scholar
• Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs67(12), 1767–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Bureik M, Hubel K, Dragan CA et al. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol. Cell. Endocrinol.217(1–2), 249–254 (2004).
   PubMed Web of Science ®Google Scholar
• Tikkanen T, Tikkanen I, Rockell MD et al. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension32(4), 778–785 (1998).
   PubMed Web of Science ®Google Scholar
• Trippodo NC, Robl JA, Asaad MM et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther.275(2), 745–752 (1995).
   PubMed Web of Science ®Google Scholar
• French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J. Cardiovasc. Pharmacol.26(1), 107–113 (1995).
   PubMed Web of Science ®Google Scholar
• Weber MA, Black H, Bakris G et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet374(9699), 1423–1431 (2009).
   PubMed Web of Science ®Google Scholar
• Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA. Cost–effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J. Clin. Hypertens. (Greenwich) 11(10), 555–563 (2009).
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet373(9671), 1275–1281 (2009).
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med.361(9), 932–934 (2009).
   PubMed Web of Science ®Google Scholar
• Frank H, Heusser K, Geiger H et al. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke40(1), 47–51 (2009).
   PubMed Web of Science ®Google Scholar